BioMarin snags first rare pediatric disease treatment approval with VIMIZEN
By Kurt R. Karst – Last Friday, BioMarin Pharmaceutical Inc. (“BioMarin”) and FDA announced (here and here) the approval of a BLA for a new biological product for patients with Mucopolysaccharidosis type IVA, also known a “Morquio A syndrome”: VIMIZEN (elosulfase alfa) Injection. The approval of VIMIZEN not only marks the first FDA-approved product for Morquio […]